Galmed Pharmaceuticals Ltd.
GLMD
$4.63
$0.8121.05%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.52% | 8.57% | 65.38% | -20.74% | 52.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.58% | 61.71% | 85.04% | 4.18% | 72.59% |
| Operating Income | -31.58% | -61.71% | -85.04% | -4.18% | -72.59% |
| Income Before Tax | -9.14% | -73.01% | -50.14% | 1.15% | -122.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.14% | -73.01% | -50.14% | 1.15% | -122.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.14% | -73.01% | -50.14% | 1.15% | -122.97% |
| EBIT | -31.58% | -61.71% | -85.04% | -4.18% | -72.59% |
| EBITDA | -- | -- | -83.78% | -3.15% | -81.91% |
| EPS Basic | 43.43% | 53.26% | 59.89% | 84.98% | 61.72% |
| Normalized Basic EPS | 28.32% | 53.26% | 63.69% | 84.98% | 69.79% |
| EPS Diluted | 43.43% | 53.26% | 59.89% | 84.98% | 61.72% |
| Normalized Diluted EPS | 28.32% | 53.26% | 63.69% | 84.98% | 69.79% |
| Average Basic Shares Outstanding | 92.95% | 270.13% | 274.27% | 558.24% | 482.64% |
| Average Diluted Shares Outstanding | 92.95% | 270.13% | 274.27% | 558.24% | 482.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |